Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BINDs President and CEO, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference in New York on Tuesday, June 24, 2014 at 10:00 a.m. ET.

Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com. The webcasts will be archived on the BIND Therapeutics website following the event for one week.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.

BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BINDs platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham (BEXP) and Womens Hospital/Harvard Medical School of BINDs scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140612006114r1&sid=acqr7&distro=nx

Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investors:
Stern Investor Relations
Paul Cox, 212-362-1200
BIND@sternir.com

Source: BIND Therapeutics, Inc.

Copyright Business Wire 2014
Comments (0)
Be the first to comment